Cincinnati Cohort Biomarker Program
Realizing the potential of precision medicine for neurodegenerative diseases
Our Great Challenge
Precision Medicine for Neurodegenerative Diseases
An estimated 80 million people worldwide live with a degenerative brain disease. What’s worse, that number will continue to grow as populations age, lifespans increase and exposures to environmental toxins rise. The burden of caring for all those individuals will put an immense strain on families and society. To rise to this challenge and stop or slow the progression of these diseases, we will need to realize the potential of precision medicine for neurodegenerative diseases.
At the moment, there are no medicines that can alter the course of degenerative brain diseases. For decades neurology has assumed that what we see in clinic will nicely match something we can measure in biology. The problem is, diseases like Parkinson’s, Alzheimer’s, ALS, etc. are umbrella terms, they do not fit the underlying biology. What we need to do is move to biologically defined diseases that we can measure and target.
To begin, we need to embrace the idea that there are likely dozens of biological pathways that lead these diseases. To slow or stop the neurodegenerative process we must develop tools to identify each disease in each individual. That will allow us to be able to match the right patient to the right therapy. Only then can we realize the potential of precision therapies for neurodegenerative diseases.
That is the mission of the Cincinnati Cohort Biomarker Program.